Global threat from drug resistant HIV in sub-Saharan Africa.
about
Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic reviewSubstandard/counterfeit antimicrobial drugsHigh-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South AfricaExposure to MIV-150 from a high-dose intravaginal ring results in limited emergence of drug resistance mutations in SHIV-RT infected rhesus macaquesOptimal starting point for antiretroviral HIV treatment in a town in Cameroon: a randomised controlled studyHIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya.Implementing antiretroviral resistance testing in a primary health care HIV treatment programme in rural KwaZulu-Natal, South Africa: early experiences, achievements and challenges.Effect of selenium supplementation on CD4+ T-cell recovery, viral suppression and morbidity of HIV-infected patients in Rwanda: a randomized controlled trialBrief Report: Virologic Monitoring Can Be a Cost-Effective Strategy to Diagnose Treatment Failure on First-Line ART.Development and evaluation of an affordable real-time qualitative assay for determining HIV-1 virological failure in plasma and dried blood spots.Characterization of novel inhibitors of HIV-1 replication that function via alteration of viral RNA processing and rev functionCombined antiretroviral and anti-tuberculosis drug resistance following incarceration.Field evaluation of dried blood spots for routine HIV-1 viral load and drug resistance monitoring in patients receiving antiretroviral therapy in Africa and Asia.Are subtype differences important in HIV drug resistance?Implementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in Africa: needs, opportunities, and challenges.Programmatic and ethical challenges in the implementation of treatment-as-prevention in the context of HIV and drug-resistant tuberculosis co-infection in sub-Saharan Africa.HIV drug resistance levels in adults failing first-line antiretroviral therapy in an urban and a rural setting in South Africa.Streptomyces spp. From Ethiopia Producing Antimicrobial Compounds: Characterization via Bioassays, Genome Analyses, and Mass Spectrometry.Implementation of a point mutation assay for HIV drug resistance testing in Kenya
P2860
Q26823588-2A2FCBA2-33F7-4B1E-8C8B-E90762E95C59Q27009319-92671118-20D4-47D8-9F1D-83935682254BQ28535483-07608806-4AFB-4068-8690-E1DC4B72A33EQ28540200-EF67DB7E-BDC0-4BEB-8321-8193D24AAF12Q34067516-D5E7FF4E-C9A9-4BE5-A459-5F3D7346DE92Q34549498-971129C8-B3B3-4C65-910B-2ED33384E56EQ35114102-9696F8E6-3701-47AA-9CB5-FCF05FC256F3Q35648928-B4BAB7C7-7295-47C7-B411-C6A5E49D3963Q36619830-02D53FE1-443F-488E-89FD-376C721D7568Q37026352-9518D293-EA58-407F-87CA-C83C76FFF26AQ37271140-BBC8C070-848A-401E-91F9-DAB2E56C423EQ37333954-6004F7FD-CE0A-4602-8B59-DA440590DBB7Q37546113-06BDDAD4-0182-41B4-841D-8FFB95335EB5Q37633109-A45995D1-6DA2-45D5-8995-B87433BE1E3DQ37634044-EFA9F3F8-7CD9-437C-B9BB-C3E86614D4A1Q38393167-CCCB4B38-76C4-4850-BE05-FB3533715B57Q39410515-AB25DA4F-1799-4A2F-BAA5-E2BC5B0A894BQ55410333-0F86F3EE-6741-4A4A-BC20-35FB96A130B0Q57131360-B2032C17-3A11-4CD7-95F0-662C7BEE8F55
P2860
Global threat from drug resistant HIV in sub-Saharan Africa.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Global threat from drug resistant HIV in sub-Saharan Africa.
@en
Global threat from drug resistant HIV in sub-Saharan Africa.
@nl
type
label
Global threat from drug resistant HIV in sub-Saharan Africa.
@en
Global threat from drug resistant HIV in sub-Saharan Africa.
@nl
prefLabel
Global threat from drug resistant HIV in sub-Saharan Africa.
@en
Global threat from drug resistant HIV in sub-Saharan Africa.
@nl
P2093
P356
P1433
P1476
Global threat from drug resistant HIV in sub-Saharan Africa.
@en
P2093
Cissy Kityo
Joep M A Lange
Peter Mugyenyi
Raph L Hamers
Tobias F Rinke de Wit
P356
10.1136/BMJ.E4159
P407
P577
2012-06-18T00:00:00Z